Local experience using botulinum toxin for the management of post-parotidectomy fistulas and recurrent parotitis

Luke M. O’Neil¹, Carsten E. Palme²³, Faruque Riffat²³, Neil Mahant⁴⁵

¹Department of Surgery, Blacktown Hospital, Sydney, Australia; ²Department of Otolaryngology, Head and Neck Surgery, Westmead Hospital, Sydney, Australia; ³Crown Princess Mary Cancer Care Centre, Westmead Hospital, Sydney, Australia; ⁴Sydney Medical School, University of Sydney, Sydney, Australia; ⁵Department of Neurology, Westmead Hospital, Sydney, Australia

Contributions: (I) Conception and design: N Mahant, LM O’Neil; (II) Administrative support: LM O’Neil; (III) Provision of study materials or patients: N Mahant, F Riffat, CE Palme; (IV) Collection and assembly of data: LM O’Neil; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Dr. Luke O’Neil. Department of Surgery, Blacktown Hospital, Blacktown, NSW, 2148, Australia. Email: lm.oneil3@gmail.com.

Background: Botulinum toxin (BTx) reduces the production of saliva in salivary glands. Literature supporting the use of BTx in post-parotidectomy fistulas and recurrent parotitis is expanding, however use in Australia has been limited. We report our experience with BTx for the management of post-parotidectomy fistulas and recurrent parotitis.

Methods: Case series. Patients were injected with onabotulinumtoxinA into the affected salivary gland or residual salivary tissue.

Results: We present nine cases of parotid gland pathology successfully managed with BTx. Five patients were managed for post-parotidectomy fistulas, with four reporting complete resolution. Four patients were managed for recurrent parotitis, all reporting reduced symptoms. In those prescribed regular antibiotics, there was a reduction in use after BTx injection. Two patients had mild dry eyes after the injections, with no other side effects.

Conclusions: We advocate for the early use of BTx in the management of post-parotidectomy fistulas and recurrent parotitis based on available data and our nine cases.

Keywords: Parotid gland; parotitis; fistula; botulinum toxin (BTx); adult

Introduction

The therapeutic indications for botulinum toxin (BTx) are expanding with literature advocating for its use in varied head and neck pathologies requiring a reduction in salivary gland output. The ability of the toxin to reduce the production of saliva was first described in research assessing the management of sialorrhea in patients with neurological conditions (1). This research initiated the novel use of BTx in the management of post-parotidectomy fistulas and recurrent parotitis as the reduction of salivary flow alleviates symptoms or allows healing.

Salivary fistulas after parotidectomy occur at a rate between 4% and 14% (2,3). The constant leak of saliva and associated increase in volume when eating can significantly impact a patient’s quality of life (4). Treatment options aim to reduce the flow of saliva through the fistula to enable tissue healing (3). A variety of treatment modalities have been described in the literature including pressure dressings, anticholinergic medications, radiotherapy, suction drain insertion or completion of the parotidectomy (4-7). Unfortunately, these management options are limited by their efficacy, side effects or expose the patient to significant risks including facial nerve injury (6-8). In contrast, BTx has been described in the literature to be effective in reducing salivary flow to enable healing of the fistula, with the largest
Demographics: All nine patients were female (mean age 59 years, range: 26–91 years). Five patients were referred to assess the change in symptoms and the presence of side effects. The study was approved by the appropriate local ethics committee.

Methods

A retrospective chart review was performed and identified nine adult patients who had salivary gland pathology managed with onabotulinumtoxinA (Botox) between November 2013 and December 2015. At time of therapy, all patients gave informed consent, including the limited evidence for its use, theoretical rationale and potential adverse effects.

Medical records were reviewed to obtain: age, primary pathology, date of first and last injection of BTx, dose, number of treatments, location of injection and time to follow-up. All patients completed a follow up questionnaire to assess the change in symptoms and the presence of side effects. The study was approved by the appropriate local ethics committee.

Results

Demographics: All nine patients were female (mean age 59 years, range: 26–91 years). Five patients were referred with a postparotidectomy fistula and four with recurrent parotitis, of which two were idiopathic, one secondary to radioiodine and the other secondary to intraglandular sialolithiasis. The cases of idiopathic recurrent parotitis were diagnosed after thorough assessments including ultrasound, CT sialography, MRI and haematological investigations, with no underlying cause identified. All injections were performed by a neurologist (NM) with extensive experience with the use of BTx for neurological disorders and sialorrhea.

Fistula group: All patients reported a fistula in the first week following their parotidectomy. Each patient was managed with a localised injection of 50 units of onabotulinumtoxinA into the residual parotid gland on the affected side under ultrasound guidance. The injections were performed in the clinic and were tolerated well. Mean time interval between onset of post-parotidectomy fistula and BTx injection was 6.4 months (range: 1–24 months). All patients reported improvement in their symptoms within one week following the injection, four with complete resolution and one with reduced salivary flow. The average follow-up for this group was 13 months (range 5 to 21 months). The patient (Table 1, case 4) who reported a reduction in salivary flow, but not complete resolution, did not return for follow up and declined further treatment. The other four patients reported complete closure of their fistula within a mean 2.5 weeks (range: 1–4 weeks) and therefore did not require further injections. All patients denied any side effects. Patient data is outlined in Table 1.

Parotitis group: Three patients with recurrent parotitis were managed with 50 units of onabotulinumtoxinA. The dose for the fourth patient was increased to 75 units following a partial response to 50 units. To confirm the anatomy of the parotid, the first injections were performed in under ultrasound guidance. All were well tolerated, and took 1–2 minutes to complete following a 3–4 minutes ultrasound to identify the anatomy. The surface landmarks were recorded diagrammatically to allow future injections with surface landmarks, with these injections typically completed within 1 minute. All patients reported an improvement with their symptoms, with one patient reporting complete resolution and three patients reporting improved symptomatology with only mild intermittent symptoms. There was a reduction in the number of courses of antibiotics the patients required, with one patient reducing from five courses a year to zero (Table 2, case 9). Another patient had a reduction from five courses to one course, which was required after symptoms started...
following an upper respiratory tract infection (Table 2, case 8). The third patient reported a reduction from two courses a year to zero (Table 2, case 6). All patients had a reduction in pain in the parotid area after BTx injections. Two patients reported mild dry eyes, with no other side effects documented. Three patients are receiving ongoing injections at 3–4 months intervals to prevent further parotitis, with no reported infections since the commencement of the injections. Patient data is outlined in Table 2.

**Discussion**

Literature for the management of recurrent parotitis and post-parotidectomy fistulas with the use of BTx is expanding. However, most studies assessing these pathologies have small sample sizes due to the rarity of the conditions. Our findings suggest that BTx may be safe and effective for the management of recurrent parotitis and post-parotidectomy fistulas as all nine patients reported symptom improvement, a finding supporting current literature.

BTx is produced by the bacterium Clostridium botulinum and irreversibly inhibits neurotransmitter release from nerve terminals, blocking neurotransmission (22). Within the salivary glands, it inhibits the release of acetylcholine in the cholinergic parasympathetic secretomotor fibres and therefore reduces the production of saliva (1). However, it does not impact on the adrenergic pathway, ensuring a
basal flow of saliva that is sufficient to avoid xerostomia (14). BTx has an onset of action on salivary glands within one week and has an expected duration of action between 3 and 5 months (23). The reduction in saliva production is presumably the basis for the improvement in both fistulae and recurrent sialadenitis, reducing flow through the fistula enables surrounding tissues to heal and preventing the pooling of saliva within the gland reducing secondary inflammation and infection (21).

All patients in our series reported a reduction in salivary flow from their fistula and four of these patients reported cessation of output and fistula resolution between 1 and 4 weeks after the BTx injection. In patients with recurrent parotitis, BTx injections reduced the number of antibiotic courses required, including one patient who was previously prescribed five courses of antibiotics each year and who subsequently did not require any further antibiotics.

The aetiology of recurrent parotitis directs the management (18-20). Two of our patients have idiopathic recurrent parotitis, confirmed after comprehensive investigations, which is managed with conservative interventions including antibiotics, oral steroids and analgesia. However, the efficacy of these interventions is poor and most patients will require formal parotid gland excision for definitive management (18). One patient had recurrent parotitis secondary to a large intraglandular sialolith, which was not amenable to sialendoscopy (19). The last patient had recurrent parotitis secondary to radioiodine accumulation, following management for thyroid carcinoma. Papers have documented promising results for the use of sialendoscopy for idiopathic and radioiodine accumulated parotitis, however our patients opted for BTx after a discussion of the management options. There is potential for BTx to be used for a range of aetiologies of recurrent parotitis given its ability to reduce salivary output and therefore reduce the pooling of saliva.

The use of BTx for recurrent parotitis is limited by its requirement for injections at three to six monthly intervals. However, the regular use of BTx is preferable over the ongoing requirement of antibiotics, given the increased risk of antibiotic resistance. Our patients also preferred the injections, given the simplicity of the injection process. We attempted to prolong the injection intervals, however when a patient reported an onset of symptoms we resumed injections at the previous interval times for that patient. One patient with recurrent parotitis required only one set of injections of BTx, with no further symptoms, an unusual occurrence that has been previously described in a case study (17).

Ultrasound guidance for injections is particularly useful when the parotid anatomy is distorted, such as post-parotidectomy and when there is substantial scarring or swelling following recurrent infections. Ultrasound may facilitate the spread of toxin through the whole gland and limit spread to surrounding structures (12). All treatments were performed in the clinic and were well tolerated. No significant side effects have been reported in the literature. In our series, two patients complained of mild transient dry eyes following injection of the toxin into the parotid, a previously unreported side effect in studies assessing BTx in parotid gland pathology. Despite a reduction in salivary flow from the injected parotid gland, no patients reported a dry mouth, suggesting that the basal flow from the parotid gland in conjunction with other salivary glands, including the contralateral parotid, provides adequate saliva to prevent xerostomia. While patients in our series with recurrent parotitis had conditions affecting unilateral parotid glands, there is potentially scope for bilateral injections of the parotid simultaneously given basal salivary flow may prevent xerostomia.

Current literature provides guidance but no clear consensus regarding the dose of BTx that should be injected for the management of either post-parotidectomy fistulas or recurrent parotitis. Our treatment protocol stipulated that we commenced all patients on an injection of 50 units into the parotid gland or residual salivary tissue, which was adequate for a clinical response in most patients. However, case 8 (Table 2) required a dose increase to 75 units due to an incomplete response to 50 units.

BTx has been recommended as a treatment option only when conservative management fails (4). In our series, management initiated before referral to our team varied, with some patients having a period of conservative management and others immediately referred. Laskawi and colleagues argue that BTx should be used in the early management of post-parotidectomy fistulas given the immediate reduction in salivary flow (3). We recommend a 4-week trial of conservative management, including pressure bandages, suturing, glycopyrrolate and diet restrictions, prior to BTx treatment. In our experience, conservative interventions seldom work. Adjuvant radiotherapy to the surgical site for patients with known malignancy typically aids fistula healing though the reduction of salivary outflow. However, patients can have associated facial and neck swelling which can impact on the design and use of the immobilisation mask and therefore alter the radiotherapy
fields. In these cases, BTx may reduce the swelling to enable better design and use of the mask.

Our study is limited by our small sample size, however given the rarity of the conditions this is expected and is demonstrated in other small published case series. Furthermore, patients completing the questionnaire about pre-BTx symptoms after the intervention is limited by their recall, however we correlated questionnaire answers with pre- and post-injection clinical notes.

Conclusions
The therapeutic scope of BTx has expanded to include recurrent parotitis and post-parotidectomy fistulas. The findings of our case series of nine patients suggest that BTx could be effective and safe in the management of post-parotidectomy fistulas and recurrent parotitis secondary to radioiodine accumulation, intraglandular sialolithisis or idiopathic, which supports the literature. We advocate for the early use of BTx in the treatment of these pathologies.

Acknowledgements
None.

Footnote
Conflicts of Interest: The authors have no conflicts of interest to declare.

Informed Consent: All patients gave informed consent, including the limited evidence for its use, theoretical rationale and potential adverse effects.

References


doi: 10.21037/ajo.2018.01.05